ArticleJournal of cosmetic dermatology2025
Oral Prescription Containing Ceramide, Proanthocyanidins, Quercetin, and Citrus Flavonoids Improves Sensitive Skin in Mice by Modulating Inflammation, Skin Barrier Function, and Gut Microbiota.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multi-omics analysis of transcriptomics and proteomics to provide mechanistic insights into the effects of camellia oil in alleviating xerosis cutis.Biochemistry and biophysics reports · 2026Article
- Quercetin alleviates incontinence-associated dermatitis via IKK/NF-κB pathway.Scientific reports · 2026Article
- Oral Prescription Containing Ceramide, Proanthocyanidins, Quercetin, and Citrus Flavonoids Improves Sensitive Skin in Mice by Modulating Inflammation, Skin Barrier Function, and Gut Microbiota.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSensitive skin is characterized by impaired skin barrier function, inflammation and dryness, and the effects of existing treatments are limited. This study explored an oral prescription containing ceramides, proanthocyanidins, quercetin, and citrus flavonoids, which inhibit inflammation, enhance barrier function, and regulate the gut-skin axis through a multi-target mechanism to improve skin sensitivity.
methodsThe therapeutic effects of the oral prescription were evaluated using the -induced AD model and the AEW-induced dry skin model. Key endpoints included skin lesion severity, TEWL, skin thickness, mast cell infiltration, inflammatory cytokine levels, and skin barrier protein expression. Microbial changes in gut flora were also assessed to evaluate the therapeutic effects of the gut-skin axis on sensitive skin.
resultsIn the AD model, oral high-dose prescription (PG-H) significantly improved skin lesions, reduced TEWL, epidermal thickness, and ear swelling, decreased mast cell infiltration and inflammatory factors (IL-4/6/31, ET-1), and enhanced barrier hydration. In the AEW model, PG-H reduced TEWL, alleviated dryness and scaling, and upregulated the expressions of filaggrin, AQP3, and loricrin, indicating a restoration of skin barrier function and relief from skin dryness. Furthermore, PG-H regulates the intestinal flora (with a reduction in Firmicutes/Bacteroides) and suggests potential therapeutic benefits for skin health.
conclusionsThe oral formulation containing ceramides, proanthocyanidins, quercetin, and citrus flavonoids improves skin barrier function, reduces inflammation, restores skin hydration, and modulates the skin-gut axis through multi-pathway and multi-target mechanisms, effectively alleviating symptoms of atopic dermatitis and dry skin, thus highlighting its potential as a novel dietary supplement for treating sensitive skin and related conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.